199 related articles for article (PubMed ID: 38216572)
21. [Polyneuropathy associated with neurofibromatosis].
Drouet A; Créange A
Rev Neurol (Paris); 2005 Mar; 161(3):275-83. PubMed ID: 15800448
[TBL] [Abstract][Full Text] [Related]
22. The Cellular Retinoic Acid Binding Protein 2 Promotes Survival of Malignant Peripheral Nerve Sheath Tumor Cells.
Fischer-Huchzermeyer S; Dombrowski A; Hagel C; Mautner VF; Schittenhelm J; Harder A
Am J Pathol; 2017 Jul; 187(7):1623-1632. PubMed ID: 28502478
[TBL] [Abstract][Full Text] [Related]
23. Neurofibromatosis 2011: a report of the Children's Tumor Foundation annual meeting.
Kalamarides M; Acosta MT; Babovic-Vuksanovic D; Carpen O; Cichowski K; Evans DG; Giancotti F; Hanemann CO; Ingram D; Lloyd AC; Mayes DA; Messiaen L; Morrison H; North K; Packer R; Pan D; Stemmer-Rachamimov A; Upadhyaya M; Viskochil D; Wallace MR; Hunter-Schaedle K; Ratner N
Acta Neuropathol; 2012 Mar; 123(3):369-80. PubMed ID: 22083253
[TBL] [Abstract][Full Text] [Related]
24. PAK1 inhibition reduces tumor size and extends the lifespan of mice in a genetically engineered mouse model of Neurofibromatosis Type 2 (NF2).
Hawley E; Gehlhausen J; Karchugina S; Chow HY; Araiza-Olivera D; Radu M; Smith A; Burks C; Jiang L; Li X; Bessler W; Masters A; Edwards D; Burgin C; Jones D; Yates C; Clapp DW; Chernoff J; Park SJ
Hum Mol Genet; 2021 Aug; 30(17):1607-1617. PubMed ID: 34075397
[TBL] [Abstract][Full Text] [Related]
25. Neurofibromatosis: part 2--clinical management.
Batista PB; Bertollo EM; Costa Dde S; Eliam L; Cunha KS; Cunha-Melo JR; Darrigo Junior LG; Geller M; Gianordoli-Nascimento IF; Madeira LG; Mendes HM; Miranda DM; Mata-Machado NA; Morato EG; Pavarino ÉC; Pereira LB; Rezende NA; Rodrigues Lde O; Sette JB
Arq Neuropsiquiatr; 2015 Jun; 73(6):531-43. PubMed ID: 26083891
[TBL] [Abstract][Full Text] [Related]
26. Current status and recommendations for biomarkers and biobanking in neurofibromatosis.
Hanemann CO; Blakeley JO; Nunes FP; Robertson K; Stemmer-Rachamimov A; Mautner V; Kurtz A; Ferguson M; Widemann BC; Evans DG; Ferner R; Carroll SL; Korf B; Wolkenstein P; Knight P; Plotkin SR;
Neurology; 2016 Aug; 87(7 Suppl 1):S40-8. PubMed ID: 27527649
[TBL] [Abstract][Full Text] [Related]
27. Genetic Counseling for Neurofibromatosis 1, Neurofibromatosis 2, and Schwannomatosis-Practice Resource of the National Society of Genetic Counselors.
Radtke HB; Bergner AL; Goetsch AL; McGowan C; Panzer K; Cannon A
J Genet Couns; 2020 Oct; 29(5):692-714. PubMed ID: 32602153
[TBL] [Abstract][Full Text] [Related]
28. The neurofibromatoses. Part 2: NF2 and schwannomatosis.
Lu-Emerson C; Plotkin SR
Rev Neurol Dis; 2009; 6(3):E81-6. PubMed ID: 19898272
[TBL] [Abstract][Full Text] [Related]
29. NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
Park HJ; Lee SJ; Sohn YB; Jin HS; Han JH; Kim YB; Yim H; Jeong SY
Int J Oncol; 2013 Feb; 42(2):657-66. PubMed ID: 23292448
[TBL] [Abstract][Full Text] [Related]
30. Cellular mechanisms of heterogeneity in NF2-mutant schwannoma.
Chiasson-MacKenzie C; Vitte J; Liu CH; Wright EA; Flynn EA; Stott SL; Giovannini M; McClatchey AI
Nat Commun; 2023 Mar; 14(1):1559. PubMed ID: 36944680
[TBL] [Abstract][Full Text] [Related]
31. Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis.
Plotkin SR; Bredella MA; Cai W; Kassarjian A; Harris GJ; Esparza S; Merker VL; Munn LL; Muzikansky A; Askenazi M; Nguyen R; Wenzel R; Mautner VF
PLoS One; 2012; 7(4):e35711. PubMed ID: 22558206
[TBL] [Abstract][Full Text] [Related]
32. Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.
Watson AL; Anderson LK; Greeley AD; Keng VW; Rahrmann EP; Halfond AL; Powell NM; Collins MH; Rizvi T; Moertel CL; Ratner N; Largaespada DA
Oncotarget; 2014 Mar; 5(6):1502-14. PubMed ID: 24681606
[TBL] [Abstract][Full Text] [Related]
33. Immortalized Human Schwann Cell Lines Derived From Tumors of Schwannomatosis Patients.
Ostrow KL; Donaldson K; Blakeley J; Belzberg A; Hoke A
PLoS One; 2015; 10(12):e0144620. PubMed ID: 26657314
[TBL] [Abstract][Full Text] [Related]
34. From process to progress-2017 International Conference on Neurofibromatosis 1, Neurofibromatosis 2 and Schwannomatosis.
Ferner RE; Bakker A; Elgersma Y; Evans DGR; Giovannini M; Legius E; Lloyd A; Messiaen LM; Plotkin S; Reilly KM; Schindeler A; Smith MJ; Ullrich NJ; Widemann B; Sherman LS
Am J Med Genet A; 2019 Jun; 179(6):1098-1106. PubMed ID: 30908866
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of YAP Sensitizes the Selumetinib Treatment for Neurofibromatosis Type 1 Related Plexiform Neurofibroma.
Tian Z; You Y; Xiao M; Liu J; Xu G; Ma C; Du Z; Wang Y
Int J Med Sci; 2023; 20(1):125-135. PubMed ID: 36619222
[No Abstract] [Full Text] [Related]
36. Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective.
Ferner RE
Lancet Neurol; 2007 Apr; 6(4):340-51. PubMed ID: 17362838
[TBL] [Abstract][Full Text] [Related]
37. NF1 gene silencing induces upregulation of vascular endothelial growth factor expression in both Schwann and non-Schwann cells.
Kawachi Y; Maruyama H; Ishitsuka Y; Fujisawa Y; Furuta J; Nakamura Y; Ichikawa E; Furumura M; Otsuka F
Exp Dermatol; 2013 Apr; 22(4):262-5. PubMed ID: 23528211
[TBL] [Abstract][Full Text] [Related]
38. MEK inhibitors enhance therapeutic response towards ATRA in NF1 associated malignant peripheral nerve sheath tumors (MPNST) in-vitro.
Fischer-Huchzermeyer S; Dombrowski A; Wilke G; Stahn V; Streubel A; Mautner VF; Harder A
PLoS One; 2017; 12(11):e0187700. PubMed ID: 29131833
[TBL] [Abstract][Full Text] [Related]
39. In vitro studies of steroid hormones in neurofibromatosis 1 tumors and Schwann cells.
Fishbein L; Zhang X; Fisher LB; Li H; Campbell-Thompson M; Yachnis A; Rubenstein A; Muir D; Wallace MR
Mol Carcinog; 2007 Jul; 46(7):512-23. PubMed ID: 17393410
[TBL] [Abstract][Full Text] [Related]
40. A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor.
Hirokawa Y; Tikoo A; Huynh J; Utermark T; Hanemann CO; Giovannini M; Xiao GH; Testa JR; Wood J; Maruta H
Cancer J; 2004; 10(1):20-6. PubMed ID: 15000491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
